Expanded access to psychedelic treatments:comparing American and Canadian policies  

作　　者：Jeremie Richard Albert Garcia-Romeu Jack E Henningfield 

机构地区：[1]Department of Psychiatry and Behavioral Sciences,Johns Hopkins School of Medicine,Baltimcre,Maryland,USA [2]Pinney Associates Inc,Bethesda,Maryland,USA

出　　处：《General Psychiatry》2025年第1期70-72,共3页综合精神医学(英文)

摘　　要：The United States Food and Drug Administration's(FDA's)August 2024 determination that an additional phase Ⅱ study will be required to consider the approval of midomafetamine for the treatment of posttraumatic stress disorder(PTSD)could delay the potential approval of this promising treatment by several years.

关 键 词：phase study canadian policies american policies expanded access posttraumatic stress disorder ptsd could FDA PTSD psychedelic treatments 

分 类 号：R749.5[医药卫生—神经病学与精神病学]